Related Experiment Video
Updated: Mar 18, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Device-Based Therapy for Drug-Resistant Hypertension: An Update.
Ping Li1,2,3, Mark Nader2, Kousalya Arunagiri2
1Washington Veterans Affairs Medical Center, 50 Irving Street, N.W., Washington, DC, 20422, USA.
Resistant hypertension (RH) is a major cardiovascular risk. Device-based therapies like renal sympathetic denervation show promise but require further validation to treat this condition effectively.
Area of Science:
- Cardiology
- Nephrology
- Hypertension Research
Background:
- Drug-resistant hypertension (RH) is a prevalent cardiovascular risk, linked to significant morbidity and mortality.
- Sympathetic nervous system over-activity is a key factor in the development and persistence of RH.
Purpose of the Study:
- To review current evidence on device-based therapies for RH.
- To identify limitations in existing trials and explore alternative approaches.
Main Methods:
- Review of clinical trials evaluating renal sympathetic denervation (RDN) and carotid baroreceptor activation therapy (BAT).
- Analysis of outcomes from recent renal denervation, carotid baroreceptor stimulation, and arteriovenous anastomosis trials.
Main Results:
- Current device-based therapies for RH, including RDN and BAT, have shown some impressive but largely uncontrolled trial outcomes needing validation.
- Device-based therapies offer potential alternative treatments for patients refractory or intolerant to medications.
Conclusions:
- Further research is essential to establish the efficacy of device-based therapies for RH in both human and animal models.
- Identifying weak links in current approaches and exploring novel strategies are crucial for advancing RH treatment.
More Related Videos
09:16A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
04:37Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Drug Therapy
Antianxiety Medications
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Therapeutic Drug Monitoring: Overview and Classification
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Direct Renin Inhibitors